• About Us
  • Activity
  • Advertising
  • Books
  • Business
  • Contact
  • EB5
  • Entertainment
  • feedback
  • Government
  • Home
  • Interviews
  • Members
  • National
  • Nevada
  • Nevada News and Views
  • Newsmax
  • NN&V Ads
  • Opinion
  • Politics
  • Polls
  • Privacy Policy
  • Subscribe
  • Subscription Confirmation
  • Survey
  • Survey
  • Terms of Service
  • Today’s Top 10
  • Travel
  • Travel
  • Travel
  • Welcome!
  • Yop Poll Archive
Nevada News and Views
  • Home
  • Muth’s Truths
  • Politics
  • Government
  • Entertainment
  • More
    • Nevada
    • Opinion
    • Business
    • Travel
    • News
    • Sports
  • Facebook

  • Twitter

  • Pinterest

  • RSS

Government

Attorney General Laxalt announces $71 million Consumer Settlement with Amgen Inc. for Deceptive Labeling

Attorney General Laxalt announces $71 million Consumer Settlement with Amgen Inc. for Deceptive Labeling
N&V Staff
August 19, 2015

Office of the Attorney General logo(Office of the Attorney General) – CARSON CITY – Today, Nevada Attorney General Adam Paul Laxalt, along with the attorneys general of 48 other states and the District of Columbia announced a $71 million settlement with Amgen Inc., a pharmaceutical company. The agreement resolved allegations that the company unlawfully promoted the drugs Aranesp and Enbrel used to treat anemia and plaque psoriasis, respectively. A complaint was filed against Amgen for marketing the two drugs using false information regarding the effects of the drugs. As a result of this settlement, Nevada will receive $939,912.45.

nevada attorney general adam laxalt“Large pharmaceutical companies have a responsibility to accurately promote their medications,” said Laxalt. “To do otherwise could jeopardize the health and well-being of Nevada’s consumers. This settlement holds Amgen accountable for its products as well as for the harm to the individuals who use them.”

The complaint and consent judgment filed alleges that Amgen violated state consumer protection laws by:

  • Promoting Aranesp on the label for dosing frequencies longer than the FDA approved label without competent and reliable scientific evidence;
  • Promoting Aranesp for anemia caused by cancer without having FDA approval or having competent and reliable scientific evidence; and
  • Promoting Enbrel for mild plaque psoriasis even though Enbrel is only approved by the FDA to treat chronic moderate to severe plaque psoriasis.

The settlement also requires Amgen to reform its marketing and promotional practices including making false or deceptive claims in promoting the drugs, or representing that the drugs have uses, benefits or qualities that they do not in fact have, among other things.

Other states participating in the settlement include: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin and Wyoming.

Chief Deputy JoAnn Gibbs of the Attorney General’s Bureau of Consumer Protection represented Nevada in this matter.

For more details on this multi-state settlement, click here.

Prev postNext post

Related ItemsAdam LaxaltAmgen Inc.attorney generalConsumer SettlementDeceptive LabelingFDA
Government
August 19, 2015
N&V Staff

Related ItemsAdam LaxaltAmgen Inc.attorney generalConsumer SettlementDeceptive LabelingFDA

More in Government

Citizen Outreach Opposes FDA’s Proposed Flavored Cigar Ban

N&V StaffAugust 5, 2022
Read More

Farm Bill: Left Sacrifices Reality to Ideology, Conservatives Should Not

N&V StaffAugust 3, 2022
Read More

Shift to Made-in-America Manufacturing Gains Steam

N&V StaffJuly 28, 2022
Read More

Rising Costs Hammering Local Small Businesses

N&V StaffJuly 18, 2022
Read More

U.S. Sugar Policy a Rare Silver Lining around Inflation’s Dark Cloud

N&V StaffJuly 10, 2022
Read More

Government Export Cap Backfires on Indian Sugar Producers

N&V StaffJuly 6, 2022
Read More
Scroll for more
Tap

Subscribe Free By Email

Looking for the best in breaking news and conservative views? Let Chuck do all the work for you! Subscribe to his FREE "Muth's Truths" e-newsletter.

* indicates required
Nevada News and Views
Nevada News & Views is an educational project of Citizen Outreach Foundation, a non-partisan IRS-approved 501(c)(3) organization. It is not associated or affiliated with any political party or group. Nevada News & Views is accessible by the public at no cost. It funds its operations through tax-deductible contributions from donors and supporters and does not accept government money or grants.

TAGS

Featured Article Nevada Politics business Muth's Truths government Government Opinion Muth’s Truths Obama Ron Knecht News Donald Trump GOP Republicans

Copyright © 2022 Citizen Outreach | Maintained by VirtualAlly

Federal agencies never let the facts get in the way of their paperwork juggernaut
Did NTIA notify Congress it unilaterally changed the IANA functions contract?